Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

DuRvalumab MEDI4730 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma A phase 3 Randomised trial (DREAM3R) (PrE0506)(PSCI#20-123)

Participants may receive the medication Durvalumab in addition to standard of care medications or standard of care medications alone for treatment of Mesothelioma.

This is a randomized study. We do not know which treatment is best for participants. Randomization means that participants will be put into two different groups for treatment. One group is the Experimental Group (standard chemotherapy with durvalumab). The other group is the Control Group (either standard chemotherapy, or immunotherapy with ipilimumab and nivolumab). Before you are randomized your Study Doctor will choose if you will receive standard chemotherapy or immunotherapy with ipilimumab and nivolumab if you are randomized to the Control Group. The results of each group are compared to see if one is better.

Patrick Ma 717-531-5471

18 year(s) or older
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
unable to surgically remove pleural mesothelioma
post menopausal or negative pregnancy test
greater than 66 pounds in weight
life expectancy of at least 12 weeks

Exclusion Criteria:
prior chemotherapy
autoimmune disease
metastasized to the brain
I'm interested
Share via email
See this study on
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,